Jack Graeber

  • Citations Per Year
Learn More
BACKGROUND Recombinant technology was used to produce a new anticoagulant that is preferentially localized and active at the site of the clot. METHODS AND RESULTS The variable regions of the heavy and light chains of a fibrin-specific antibody were amplified by polymerase chain reaction (PCR) with hybridoma cDNA. To obtain a functional single-chain(More)
BACKGROUND Targeting of plasminogen activators to the fibrin component of a thrombus by antibodies directed against human fibrin can enhance their thrombolytic potency and clot specificity. OBJECTIVES To overcome the disadvantages of chemical conjugation, we investigated whether the recombinant fusion of a single-chain antibody and a plasminogen activator(More)
In light of the theory of prostaglandin (PG) mechanism of action as removal of a progesterone block mediating myometrial stimulation, the effect of PGF2alpha on hormonal patterns was analyzed in 8 patients between 11.5 and 18.5 weeks of gestation. PGF2 alpha was administered intravenously by pump and blood samples were drawn hourly during the first 12(More)
Surfactant administration for respiratory distress syndrome continues to make an impact on neonatal care as large controlled trials are published. Although considered safe, synthetic surfactant administration has been associated with a rare complication in the form of pulmonary hemorrhage. Despite this, significant benefits have been shown. With the(More)
This action was filed as a putative securities fraud class action. Essentially, the Complaint alleges that Plaintiff and others purchased Scientific-Atlanta, Inc. ("SA") securities at an artificially inflated price as a result of false and misleading representations made by the persons controlling S-A during the relevant time period, Now before the Court(More)
  • 1